NKGen Biotech Inc Stock Price, News & Analysis

NKGen Biotech (Nasdaq: NKGN) will present new biomarker data on its SNK01 therapy for Alzheimer's disease at the 2024 Alzheimer's Association International Conference. The poster presentation will showcase SNK01's ability to reduce α-synuclein in Alzheimer's patients, which is significant as α-synuclein correlates with worse cognitive function. The presentation, titled 'Subjects treated with expanded non-genetically modified autologous Natural Killer cells (SNK01) show improved changes in CSF α-synuclein and in cognitive function,' will be held on July 30, 2024. This data adds to previously disclosed Phase 1 results showing SNK01's positive effects on amyloid, tau, and neuroinflammation biomarkers in Alzheimer's patients.

NKGen Biotech (Nasdaq: NKGN) has appointed Dr. Marco Gottardis to its Board of Directors, effective July 11, 2024. Dr. Gottardis will serve on the company's Audit, Compensation, and Nominating and Corporate Governance Committees. He brings extensive experience in biopharmaceuticals and oncology research, having held senior positions at Replay Bio Holdings and Janssen Pharmaceuticals. Dr. Gottardis has a PhD in Human Oncology and has led strategies for novel research platforms and prostate cancer R&D portfolios.

NKGen's CEO, Dr. Paul Y. Song, expressed enthusiasm about Dr. Gottardis joining the board, highlighting his expertise in cell therapy research and development. This appointment is expected to strengthen NKGen's capabilities as they advance their NK cell therapy clinical programs in neurodegenerative diseases and cancer.

NKGen Biotech presented updated Phase 1 data on its allogeneic NK cell therapy, SNK02, at the 6th Annual Allogeneic Cell Therapies Summit 2024. The therapy avoids lymphodepletion, aiming to preserve immune function and reduce toxicity. In the trial, 6 patients with advanced solid tumors received weekly intravenous doses of SNK02. Four patients completed 8 cycles, with stable disease observed in all. The treatment was generally well-tolerated, with most adverse events being mild. One death occurred but was deemed unrelated to the therapy. Further studies will explore SNK02 in combination with other immunotherapies.

NKGen Biotech (Nasdaq: NKGN) announced that CEO Paul Y. Song, MD, will present updated Phase 1 data on their SNK02 allogeneic NK cell therapy at the 6th Annual Allogeneic Cell Therapies Summit, June 10-12, 2024, in Boston, MA. The presentation, scheduled for June 12, will highlight the company's cryopreserved allogeneic NK cell therapy platform and the initial Phase 1 results for advanced refractory solid tumors. Dr. Song will discuss the potential benefits of eliminating pre-treatment lymphodepletion, which may reduce toxicity and preserve immune function. Further, the presentation will explore unexpected findings from the SNK02 trial that suggest its use beyond cancer treatment. A copy of the presentation will be available on the company's website post-event.

NKGen Biotech has announced interim results from its Phase 1 clinical trial of SNK02, an allogeneic NK cell therapy for advanced solid tumors, at the 2024 ASCO Annual Meeting.

The trial showed that SNK02 was well-tolerated and demonstrated a stable disease response in 100% of patients completing 8 treatment cycles. The study involved five patients with refractory solid tumors, averaging four prior lines of therapy, and a median age of 64.

SNK02 did not require lymphodepletion before administration and exhibited some clinical activity as a monotherapy. Adverse events were mostly mild with one Grade 3 event resolving without intervention.

The company plans to continue studying SNK02 in combination with monoclonal antibodies and immune checkpoint inhibitors.

NKGen Biotech announced that its cryopreserved, enhanced natural killer cell therapy, SNK01, has been cleared to progress into Phase 2 clinical trials for moderate Alzheimer’s disease. The therapy showed clinical benefit and no drug-related adverse events in Phase 1. The Phase 2 trial will involve 30 patients, with 20 receiving SNK01 and 10 receiving a placebo, and will begin in Q2 2024. This trial aims to assess the therapy's efficacy and safety over a full year. Preliminary results are promising, with improvements in cognitive function and daily activities observed.

NKGen Biotech, a clinical-stage biotech company, will present its autologous NK cell therapy, SNK01, at the 5th International Cell & Gene Therapy China Summit. SNK01, which shows enhanced cytotoxicity and receptor expression, targets neurodegenerative diseases and solid tumors. CEO Paul Y. Song will discuss manufacturing advances and results combining SNK01 with immune checkpoint inhibitors and Erbitux for resistant cancers. The presentation, set for May 23, 2024, will also highlight SNK01's potential against multiple neurodegenerative diseases by improving key protein levels.

NKGen Biotech, Inc. (NKGN) received FDA clearance for its SNK01 NK cell therapy in Parkinson's disease, advancing its neurodegenerative disease program. The Phase 1/2a clinical trial is set to commence in 2H 2024, with SNK01 showing promising potential in addressing Parkinson's disease through enhanced cytotoxicity and activating receptor expression.